Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC boosted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 11.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 205,391 shares of the biotechnology company’s stock after buying an additional 21,640 shares during the period. Voya Investment Management LLC owned 0.32% of Blueprint Medicines worth $17,914,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Torray Investment Partners LLC increased its position in shares of Blueprint Medicines by 1.1% during the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after purchasing an additional 186 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after buying an additional 265 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company’s stock valued at $580,000 after buying an additional 283 shares during the last quarter. Pitcairn Co. lifted its stake in shares of Blueprint Medicines by 2.8% in the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company’s stock worth $925,000 after buying an additional 293 shares in the last quarter. Finally, Hillsdale Investment Management Inc. boosted its position in Blueprint Medicines by 0.6% during the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company’s stock worth $4,433,000 after acquiring an additional 310 shares during the last quarter.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 3,203 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares of the company’s stock, valued at $6,581,655.32. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $87.66 on Monday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market cap of $5.60 billion, a P/E ratio of -81.17 and a beta of 0.75. The stock has a 50-day moving average of $87.57 and a two-hundred day moving average of $93.18. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analysts Forecast Growth

BPMC has been the topic of a number of research reports. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating on the stock. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Scotiabank started coverage on Blueprint Medicines in a report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price target on shares of Blueprint Medicines in a report on Tuesday, April 8th. Finally, StockNews.com cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.68.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.